Induction of the transcription factor Irf8 in the common dendritic cell progenitor (CDP) is required for classical type 1 dendritic cell (cDC1) fate specification, but the mechanisms controlling this induction are unclear. In the present study Irf8 enhancers were identified via chromatin profiling of dendritic cells and CRISPR/Cas9 genome editing was used to assess their roles in Irf8 regulation. An enhancer 32 kilobases (kb) downstream of the Irf8 transcriptional start site (+32-kb Irf8) that was active in mature cDC1s was required for the development of this lineage, but not for its specification. Instead, a +41-kb Irf8 enhancer, previously thought to be active only in plasmacytoid dendritic cells, was found to also be transiently accessible in cDC1 progenitors, and deleting this enhancer prevented the induction of Irf8 in CDPs and abolished cDC1 specification. Thus, cryptic activation of the +41-kb Irf8 enhancer in dendritic cell progenitors is responsible for cDC1 fate specification.
T he diversification of immune cells relies on lineage-determining transcription factors (TFs) that commit multipotent progenitors to a single fate 1, 2 . Although early studies proposed that stochastic variations in the levels of these factors determined the eventual fate of progenitors 3 , more recent work has suggested rather that the expression of individual factors is actively induced to specify a particular lineage 4 . However, the precise mechanisms responsible for such induction remain unclear.
Gene expression is primarily controlled by cis-acting enhancers bound by TFs 5 . Certain genes are regulated entirely by a single enhancer 6, 7 , whereas others, including many genes important for development, contain multiple, potentially redundant enhancers as a safeguard for continued expression 8, 9 . Furthermore, enhancer usage in individual genes dynamically changes as progenitors mature, possibly indicating the actions of distinct transcriptional networks throughout the developmental progression of a cell type 10 . Analysis of the enhancers that regulate expression of lineage-determining TFs at developmental branch points could therefore identify the transcriptional mechanisms controlling fate choice.
Dendritic cells (DCs) are a group of immune cells critical for innate and adaptive immune responses that include 'classical' DCs (cDCs) 11 and plasmacytoid DCs (pDCs) 12 . cDCs comprise two functionally distinct lineages called cDC1 and cDC2 (ref. 13 ). cDC1s are critical for priming CD8 T cells during antiviral and antitumor immune responses 14 , as well as for effective responses to checkpoint blockade therapy 15, 16 . cDC1s are also the most promising substrates for cell-based cancer vaccines 17 , so understanding their development is paramount.
DCs are derived from hematopoietic precursors in the bone marrow (BM), the earliest of which is the monocyte/DC progenitor (MDP) 18 . The MDP gives rise to a common DC progenitor (CDP) 19, 20 , which produces distinct clonogenic progenitors, the precDC1 and the pre-cDC2 (refs. 21, 22 ). Several TFs regulate development of the cDC1 lineage, including those encoded by the genes Irf8, Batf3, Nfil3 and Id2 (refs. 14, [23] [24] [25] ). Although cDC1s can be generated in mice deficient in Nfil3, Batf3 or Id2 under inflammatory conditions 26, 27 , Irf8 -/-mice have an absolute defect in both pre-cDC1 specification and cDC1 development that cannot be rescued by such conditions. Furthermore, the Irf8 gene contains a super-enhancer in cDC1s, and Irf8 overexpression biases BM progenitors toward cDC1 output 21 . These properties together suggest that Irf8 is the lineage-determining TF for cDC1 fate. Understanding the enhancers that regulate Irf8 could therefore provide insight into how cDC1 fate specification from its multipotent progenitor, the CDP, is achieved.
Previous work by the authors of the present study identified two distinct enhancers within the Irf8 super-enhancer located at +32 kilobases (kb) and +41 kb relative to the Irf8 transcriptional start site (TSS) 21 . Using an integrating retroviral reporter, it was demonstrated that the +32-kb Irf8 enhancer was selectively active in cDC1s and that the +41-kb Irf8 enhancer was selectively active in pDCs. The +32-kb Irf8 enhancer contained several AP1-IRF composite elements (AICEs) that bound interferon regulatory Cryptic activation of an Irf8 enhancer governs cDC1 fate specification Vivek Durai 1 factor 8 (IRF8) and basic leucine zipper transcription factor ATFlike 3 (BATF3) in cDC1s by chromatin immunoprecipitation sequencing (ChIP-seq), suggesting that this enhancer might support Irf8 expression through autoactivation. The +41-kb Irf8 enhancer contained several E-box motifs, suggesting that E-proteins such as E2-2, the lineage-determining TF of pDCs 28 , might utilize this enhancer to drive Irf8 expression in pDCs. Finally, an Irf8 enhancer located at −50 kb was identified and analyzed using bacterial ). e, Growth of regressor fibrosarcoma 1969 in WT and Irf8 +32 kb -/-mice. Data are pooled from two independent experiments (n = 8 mice for WT and n = 8 mice for Irf8 +32 -/-). NS, not significant (P > 0.05); *P < 0.05; ****P < 0.0001, ordinary one-way ANOVA (d).
artificial chromosome (BAC) reporter transgenic mice, and was predicted to be required for Irf8 expression in MDPs 29 . However, until now the functional requirement of these Irf8 enhancers for in vivo DC development has remained untested.
In the present study, chromatin profiling of DCs and CRISPR/ Cas9 genome editing were used to identify and delete enhancers regulating Irf8 in mice. It was found that the +32-kb Irf8 enhancer was required for normal and compensatory cDC1 development, but not for pre-cDC1 specification. It was also found that the −50-kb Irf8 enhancer was not required for Irf8 expression in MDPs, as was previously predicted, but rather regulated Irf8 levels selectively in monocyte/macrophage lineages. To find other enhancers regulating the cDC1 lineage, ATAC-seq was performed on DC progenitors. Surprisingly it was found that the +41-kb Irf8 enhancer became transiently accessible during the transition from the MDP to the pre-cDC1, before again closing in the mature cDC1. Deletion of the +41-kb Irf8 enhancer led to decreased Irf8 expression in pDCs, as was predicted, but also surprisingly prevented Irf8 induction in CDPs, resulting in the loss of both pre-cDC1 and mature cDC1 development. Consistently, Tcf3 -/-DC progenitors, which lack E2A, had reduced cDC1 potential. Thus, cryptic activation of the +41-kb Irf8 enhancer within CDPs is required for the induction of Irf8 and the subsequent specification of cDC1 fate.
Results
The +32-kb Irf8 enhancer is required for cDC1 development in vivo. The +32-kb Irf8 enhancer was identified using ChIP-seq as a 547-base-pair (bp) region that bound the TFs BATF3, IRF8 and p300 in cDC1s, and contained four AICEs in the 5′-portion of the region 21 ( Fig. 1a) . Reporter analysis indicated that the first three AICEs within this region were sufficient to confer cDC1-specific reporter activity, and that this activity could be abrogated by mutating these three AICEs (see Supplementary Fig. 1a,b) . The four AICEs contained in the 5′-portion of the +32-kb Irf8 enhancer also accounted for the entire activity of the full-length enhancer (see Supplementary Fig. 1c) . Furthermore, using Fms-related tyrosine kinase 3 ligand (Flt3L)-treated BM cultures of R26 Cas9/+ transgenic mice, in which Cas9 is constitutively expressed in all cells under the control of the Rosa26 promoter 30 , it was found that expression of a single guide RNA (sgRNA) directed to the central AICE in the 5′-half of the +32-kb Irf8 enhancer caused a reduction in cDC1 development that was as large as the reduction caused by an sgRNA directed at the Irf8-coding sequence itself (see Supplementary  Fig. 1d ). Therefore mice were generated with deletions in this region by injecting zygotes with Cas9 messenger RNA (mRNA) and three sgRNAs, two flanking the first three AICEs in the 5′-half of the enhancer and a third downstream of the fourth AICE (Fig. 1a and see Supplementary Fig. 1e ). This generated two lines of mice with deletions within the +32-kb Irf8 enhancer, one deleting 149 bp and eliminating three AICEs (Irf8 +32 5′ -/-mice), and a second deleting 421 bp and eliminating all four AICEs (Irf8 +32 -/-mice) (see Supplementary Fig. 1f ). Both lines showed severe reductions in cDC1 development in vivo (see Supplementary Fig. 1g,h ). Deletion of three AICEs reduced cDC1 development by tenfold compared with wild-type (WT) mice, and deletion of all four AICEs eliminated all residual cDC1s (see Supplementary Fig. 1h ). All subsequent analyses used the more complete Irf8 +32 -/-strain. The defect in splenic cDC1 development in Irf8 +32 -/-mice was more complete than in Batf3 -/-mice and as severe as in Irf8 -/-mice (Fig. 1b,d ). Irf8 +32 -/-mice showed no defects in other lineages, confirming the selective activity of this enhancer in cDC1s, as was predicted by the authors' reporter assays. pDCs were normal in frequency and in intracellular IRF8 protein levels (Fig. 1c,d ), as were monocytes, neutrophils, red pulp macrophages, B cells and T cells (see Supplementary Fig. 2a-c) . cDC1s in Irf8 +32
-/-mice were absent in all tissues, such as the lung (see Supplementary Fig. 3a,b) . To test for a functional defect in Irf8 +32
-/-mice, a tumor rejection system that requires cDC1s was used (Fig. 1e) . The regressor fibrosarcoma 1969, the rejection of which relies on cross-presentation by cDC1s 31 , was rejected by all WT mice, but not by Irf8 +32 -/-mice (Fig. 1e ). These data indicated that the +32-kb Irf8 enhancer was absolutely required for cDC1 development and that its deletion generated a specific and functional defect restricted to this lineage.
Compensatory cDC1 development requires the +32-kb Irf8 enhancer. cDC1 development can occur in Batf3 -/-mice due to compensation from BATF and BATF2, which can replace BATF3 for interactions with IRF8 (ref. 26 ). Compensatory cDC1 development in Batf3 -/-mice occurs in skin-draining lymph nodes (SLNs), under inflammatory settings such as after BM transplantation, and after administration of interleukin (IL)-12 (refs. 26, 27 ). These settings were examined to test whether compensatory cDC1 development can occur in Irf8 +32 -/-mice (Fig. 2 ). cDC1s were present in SLNs from WT and Batf3 -/-mice, but were completely absent in SLNs from Irf8 +32 -/-mice (Fig. 2a,b) . Furthermore, administration of IL-12 led to a complete restoration of splenic cDC1s in Batf3 -/-mice but not in Irf8 +32
-/-mice ( Fig. 2c,d ). Finally, cDC1 compensation was examined after BM transplantation 27 . BM chimeras were generated using WT, Irf8 +32 -/-or Batf3 -/-donor BM transplanted into irradiated WT mice (see Supplementary Fig. 3c,d ). cDC1s developed in chimeras produced from WT BM, as expected, and from Batf3 -/-BM, as reported 27 . However, cDC1s failed to develop in chimeras produced from Irf8 +32 -/-BM. In summary, all compensatory cDC1 development failed to occur in mice lacking the +32-kb Irf8 enhancer.
Although IL-12 injection did not restore cDC1s in Irf8 +32 -/-mice, it did increase the numbers of cDC2s (Fig. 2c,d ). This potentially ). NS, not significant (P > 0.05); *P < 0.05, **P < 0.01 and ****P < 0.0001; ordinary one-way ANOVA (b) or unpaired, two-tailed, Student's t-test (d).
resulted from specified pre-cDC1s failing to maintain high Irf8 levels in response to IL-12 and subsequently being diverted to the cDC2 fate, as occurs with pre-cDC1s from Batf3 -/-mice 21 . It was therefore necessary to determine whether pre-cDC1 specification occurs in Irf8 +32 -/-mice. Previous identification of pre-cDC1s in BM had relied on Zbtb46-GFP expression. To identify pre-cDC1s without using the Zbtb46-GFP strain, a method was developed to identify pre-cDC1s using an alternate marker (see Supplementary  Fig. 4 ). Microarray analysis revealed that the gene encoding the surface glycoprotein CD226 was not expressed in CDPs, but became expressed in pre-cDC1s (see Supplementary Fig. 4a,b) 21 . Through the use of CD226 expression, pre-cDC1s were found to develop in Irf8 +32
-/-mice in normal numbers but with reduced intracellular IRF8 protein levels (Fig. 2e ,f, and see Supplementary Fig. 3e ), similarly to the findings in Batf3 -/-mice. In contrast to WT pre-cDC1s, pre-cDC1s from Irf8 +32 -/-mice cultured in Flt3L become cDC2s I r f 8 Fig. 2g ). These cDC2s derived from Irf8 +32 -/-pre-cDC1s were transcriptionally similar to cDC2s arising from WT pre-cDC2s and transcriptionally distinct from cDC1s arising from WT pre-cDC1s, including in the expression of key cDC2 TFs such as Irf4 (see Supplementary Fig. 4e-g ). Although the cDC2s derived from Irf8 +32
-/-pre-cDC1s retained CD24 expression, there were no transcriptional differences between CD24 + cDC2s and CD24 -cDC2s (see Supplementary Fig. 4f ), indicating that the diverted cDC2s that developed from Irf8 +32 -/-pre-cDC1s were bona fide cDC2s. This result also recapitulated the diversion of Batf3 -/-precDC1s to a cDC2 fate (see Supplementary Fig. 4h ). In summary, Irf8 +32 -/-mice showed continued development of a specified pre-cDC1 progenitor in BM that fails to sustain Irf8 expression and diverts to the cDC2 lineage.
The −50-kb Irf8 enhancer regulates Irf8 expression in monocytes and macrophages. To identify enhancers regulating pre-cDC1 specification, ChIP-seq of active histone marks was performed in MDPs, CDPs and pre-cDC1s. This analysis identified a region of active H3K27 acetylation at −50 kb relative to the Irf8 TSS that overlapped with a previously identified Irf8 enhancer (Fig. 3a ) 29 . Analysis of BAC transgenic Irf8 reporter mice had suggested that this −50-kb region contains two PU.1-binding sites and was required for Irf8 expression in the MDP 29 . To test whether this enhancer regulated Irf8 induction and pre-cDC1 specification, CRISPR/Cas9 genome editing was used to generate mice with a 364-bp deletion that eliminated both of the PU.1 sites in this region (Irf8 −50 -/-mice) (see Supplementary Fig. 5a ,b). Irf8 −50 -/-mice had normal frequencies of cDCs, pDCs, neutrophils, B cells, T cells and red pulp macrophages ( Fig. 3b and see Supplementary Fig. 5c ), all of which had normal levels of intracellular IRF8 protein ( Fig. 3c and see Supplementary Fig. 5d ). Frequencies and intracellular IRF8 protein levels of MDPs, CDPs and pre-cDC1s were also normal in Irf8 −50 -/-mice (Fig. 3d,e) , in contrast to the predictions based on the BAC transgenic Irf8 reporter mice 29 . However, ATAC-seq analysis suggested that the −50-kb Irf8 enhancer was active in F4/80 + peritoneal macrophages and Ly6C + monocytes (Fig. 4a) . In Irf8 −50 -/-mice, monocytes were present at normal numbers, but showed reduced intracellular IRF8 protein levels compared with WT mice (Fig. 4b-d) . Likewise, F4/80 + peritoneal macrophages in Irf8 −50 -/-mice had greatly reduced intracellular IRF8 protein levels (Fig. 4e,f) . Irf8 -/-mice have been reported to have decreased survival in Salmonella enterica serovar typhimurium infection, possibly due to IRF8 regulation of inflammasome activity in macrophages 32 . However, it was not determined whether the survival defect in germline Irf8 -/-mice was because of the loss of IRF8 specifically in macrophages. Irf8 −50 -/-mice were found to be more susceptible to Salmonella infection compared with WT mice (Fig. 4g) , confirming the importance of the −50-kb Irf8 enhancer and of IRF8 activity in macrophages for host defense against this pathogen. In conclusion, the −50-kb Irf8 enhancer was not required for DC development, but did regulate Irf8 specifically in monocytes and macrophages.
ATAC-seq reveals transient use of the +41-kb Irf8 enhancer during cDC1 development. To obtain basepair-level resolution of accessible chromatin in progenitors, ATAC-seq was performed on MDP, CDP and pre-cDC1 populations (Fig. 5 ) 33, 34 . Pearson's correlation analysis of all distal ATAC-seq peaks indicated that MDPs were most closely related to CDPs and least related to pre-cDC1s (Fig. 5a ). During transition from MDPs to CDPs, 687 unique peaks were gained and 1,522 lost (Fig. 5b) . By contrast, during transition from CDPs to pre-cDC1s, 14,630 peaks were gained and 13,664 lost. Thus, a large shift in chromatin accessibility occurs as CDPs transition to pre-cDC1s, which could potentially be related to the loss of alternative fate potentials in the pre-cDC1s, to the differential proliferative capacities of these two cell types or to a natural consequence of the differentiation process.
Five main k-means clusters of peaks were identified (Fig. 5c ). Cluster 1 included peaks found only in MDPs. Clusters 2 and 3 included peaks shared between MDPs and CDPs. Cluster 4 contained peaks found in both CDPs and pre-cDC1s, and cluster 5 included peaks present only in pre-cDC1s. The genes closest in linear distance to the peaks within each cluster were identified, and the TF motifs enriched within these peaks were inferred (Fig. 5c,d ). Of note, the enrichment of TFs reflects the activity of any factor with a similar DNA-binding motif rather than the activity of the specific factor that was enriched. For example, enrichment of Tcf3 could reflect the activity of other Tcf factors such as Tcf4 or Tcf12 within the clustered peaks. Peaks unique to MDPs (cluster 1) were in proximity to genes related to monocyte ontogeny, such as Mpo and Maf. These peaks were enriched in motifs for TFs such as Cebpb and Atf that regulate the macrophage/monocyte lineages 35, 36 ( Fig. 5c,d ). The peaks identified in MDPs and CDPs (clusters 2 and 3) were enriched for motifs binding E-proteins and Runx factors, both of which are required for DC development 28, 37, 38 (Fig. 5c,d ). Runx1 was also among the genes most proximal to peaks within these clusters, and the Runx1 locus contained open chromatin peaks in the MDP and CDP that were lost in the pre-cDC1 (Fig. 5e) .
The peaks found in CDPs and pre-cDC1s (cluster 4) were also enriched in motifs binding E-proteins (Fig. 5c) . Furthermore, cluster 4 included the +41-kb Irf8 enhancer (Fig. 5c ), which contains six predicted E-box motifs and was previously found to be active in pDCs but not in cDC1s 21 ( Fig. 1a) . This unexpected ATAC-seq accessibility of the +41-kb Irf8 enhancer in the pre-cDC1 (Fig. 5e) suggested that the activity of this enhancer could be important for cDC1 specification.
Finally, in the cluster of peaks found only in the pre-cDC1 (cluster 5), Irf8 and Batf3 were among the genes at closest proximity to open regions and AP1-IRF motifs and PU.1 motifs were highly enriched within these regions (Fig. 5c,d ). Accessible chromatin peaks were also proximally located to genes known to be critically involved in cDC1 function, such as Wdfy4 (ref. 39 ) (Fig. 5e ). Furthermore, it was found that the +32-kb Irf8 enhancer became accessible only at the pre-cDC1 stage (Fig. 5c,e) . Together, the data suggest that the +41-kb Irf8 enhancer was transiently active in cDC1 progenitors before being replaced by activity at the +32-kb Irf8 enhancer in mature cDC1s.
The +41-kb Irf8 enhancer is required for cDC1 fate specification. By ATAC-seq analysis, the +41-kb Irf8 enhancer was inactive in MDPs, became active in CDPs and pre-cDC1s, and was inactive again in mature cDC1s (Fig. 6a) . This enhancer also bound p300 in pDCs, suggesting that it regulated Irf8 expression in these cells 21 . This enhancer was targeted using CRISPR/Cas9 genome editing with two flanking sgRNAs (Fig. 6a) , producing mice with a 361-bp deletion (Irf8 +41 -/-) that eliminated all six predicted E-boxes (see Supplementary Fig. 6a,b) . As expected, Irf8 +41 -/-mice had a pDC phenotype similar to the phenotype reported for Irf8 -/-mice 40 . pDCs were present in Irf8 +41 -/-mice, but had low levels of IRF8 and CD317 and increased levels of IRF4 (Fig. 6b-d) . By contrast, monocytes, neutrophils, red pulp macrophages, B cells and T cells from these mice were normal in frequency and intracellular IRF8 protein levels (see Supplementary Fig. 6c,d ). Unexpectedly, Irf8 +41 -/-mice completely lacked mature cDC1s (Fig. 6b,d ). MDPs and CDPs continued to develop at normal frequencies in the BM of Irf8 +41 -/-mice, however, indicating that the +41-kb Irf8 enhancer was not required for the development of these progenitors (Fig. 6e) . But while the transition from the MDP to the CDP is usually accompanied by an approximately twofold increase in intracellular IRF8 protein levels in WT CDPs, there was no increase in IRF8 levels in Irf8 +41 -/-CDPs (Fig. 6f) . Also, pre-cDC1s failed to develop in Irf8 +41 -/-mice, similar to Irf8 -/-mice (Fig. 6g) . In summary, the +41-kb Irf8 enhancer was only transiently active during cDC1 progenitor development, and yet was absolutely required for Irf8 induction in the CDP and for cDC1 fate specification.
E-proteins are involved in cDC1 and pDC development. As deletion of the +41-kb Irf8 enhancer abolished cDC1 specification, the factors that bound to this enhancer could be responsible for inducing cDC1 fate choice. The 454-bp region defining this enhancer contains six predicted E-box motifs (Fig. 6a) 
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. ChIP-seq of lipopolysaccharide (LPS)-activated B cells, pre-plasmablasts and plasmablasts, in which E-proteins and IRF8 are active, showed E2A binding to the +41-kb Irf8 enhancer. ATAC-seq of these populations also found that this site was accessible in WT B cells, but was not in B cells doubly deficient for the E-proteins E2A (Tcf3) and E2-2 (Tcf4) (Fig. 7a) .
The E-proteins E2A and E2-2 are known to regulate B cell development and pDC development, respectively 28, 41 , but they have not been implicated in cDC development or function. Using the Tcf3 fl/+ VavCre tg mice, which express an E2A-GFP fusion protein after Cre activity 41 , it was found that E2A was expressed highly in MDPs and CDPs, had reduced expression in pre-cDC1s and was completely absent in mature cDC1s and pDCs (Fig. 7b) . This indicated that there was a transient period of E2A expression in DC progenitors. E2A was also expressed in pre-B cells, as has been previously described 41 , and also in common myeloid progenitors (CMPs) and common lymphoid progenitors (CLPs) (see Supplementary  Fig. 7a ). To test the relevance of this expression, DC development from WT and Tcf3 -/-BM was analyzed using Flt3L-treated cultures. While WT BM showed normal cDC1 and pDC development in vitro, Tcf3 -/-BM showed severely impaired development of both populations while retaining normal cDC2 development (Fig. 7c,d ). However, cDC1s and pDCs continued to develop in Tcf3 -/-mice in vivo, suggesting possible compensation for the actions of Tcf3 by another member of the Tcf family, as has been previously described in B cells 42 (see Supplementary Fig. 7b,c) . To further characterize the role of Tcf3 in vivo, BM chimeras were generated with mixed WT and Tcf3 -/-BM and DC development was assessed after reconstitution (see Supplementary Fig. 7d,e) . It was found that WT progenitors preferentially gave rise to cDC1s and exclusively gave rise to pDCs when in competition with Tcf3 -/-progenitors. These results suggest a potential role for E-proteins in cDC1 and pDC development.
Discussion
The present study analyzed the in vivo function of three different Irf8 enhancers, discovering unexpected and distinct roles in DC development and monocyte/macrophage function for each. The initial aim was to understand the development of the cDC1 subset critical for antiviral and antitumor immunity. Irf8 is the lineagedetermining TF responsible for cDC1 development 23 , but the molecular regulation of its transcription has not been well characterized. Previous studies have proposed that PU.1 regulated the induction of Irf8 in the MDP through a −50-kb Irf8 enhancer 29 , that BATF3 supported Irf8 autoactivation at the +32-kb Irf8 enhancer 21 , and that there was a pDC-specific +41-kb Irf8 enhancer as well 21 . However, none had tested the roles of any Irf8 enhancer elements in vivo.
In the present study, several targeted deletions of Irf8 enhancers were generated using CRISPR/Cas9 genome editing in mice. The results have confirmed the +32-kb Irf8 enhancer's role in cDC1 development 21 and excluded a role for the −50-kb Irf8 enhancer in early Irf8 expression 29 . However, most importantly, the analysis has established a wholly unexpected requirement for the +41-kb Irf8 enhancer in Irf8 induction within the CDP and subsequent cDC1 fate specification. This further suggested a previously unrecognized role for E-proteins in this process as well.
The +32-kb Irf8 enhancer was shown to be required for normal and compensatory cDC1 development. Originally, this result had been predicted because BATF3, which is required for cDC1 development, bound along with IRF8 to the +32-kb Irf8 enhancer. However, it was possible that BATF3 could also interact with other unidentified regions that serve as redundant enhancers to support cDC1 development. The present study confirmed that the +32-kb Irf8 enhancer was absolutely required for normal cDC1 development, as well as for the compensatory cDC1 development that can occur in Batf3 -/-mice under various inflammatory settings. As a result of this compensatory cDC1 development, this strain has not been useful for examining the function of cDC1s in some settings.
For example, during Mycobacterium tuberculosis infection cDC1s reappear in Batf3
-/-mice, meaning this strain cannot be used to evaluate how absence of these cells affects host defense 26 . In addition, Batf3 has functions in other lineages, such as T cells and perhaps macrophages 43 , so Batf3 -/-mice might have defects in other cell types that make interpretations from this strain difficult. These limitations have been resolved by the generation of Irf8 +32 -/-mice. In these mice, Batf3 is expressed normally in all immune lineages, but cDC1 development, both natural and compensatory, is ablated. These mice should now allow for the analysis of cDC1 function in settings where it could not previously be studied.
The results of the present study also demonstrate how the cryptic activation of enhancers by transiently active transcriptional networks can control lineage diversification. Early models of hematopoiesis proposed that the fate choices of progenitors are resolved by stochastic fluctuations in the expression of cross-antagonistic lineage-determining TFs. These fluctuations cause one factor to become dominant and impose fate commitment, which is reinforced by autoactivation of this factor and cross-inhibition of opposing factors. One example is the PU.1/GATA1 circuit that regulates the choice between myeloid and megakaryocyte/erythrocyte fates. PU.1 and GATA1 can inhibit each other 44, 45 and also activate their own transcription 46, 47 . Furthermore, these factors were thought to be co-expressed in progenitor cells that remained uncommitted until fluctuations in the levels of these two factors specified them to a single fate 3 . However, this model was challenged by a recent study that used high-resolution analysis of single progenitor cells 4 . Using reporters for PU.1 and GATA1 expression, the study demonstrated that no progenitor cells actually co-express these factors. Rather, PU.1 levels decay before GATA1 is even expressed in progenitors destined for megakaryocyte/erythrocyte fate. This suggested that some unknown mechanism actually drives this particular cell fate by inducing GATA1, rather than stochastic fluctuations randomly generating this outcome. The data of the present study also support such a deterministic rather than stochastic model of fate divergence, in which transiently active transcriptional networks initiate the higher expression of lineage-determining TFs. Specifically, it was ). NS, not significant (P > 0.05); *P < 0.05; ****P < 0.0001, ordinary one-way ANOVA (d).
found that activation of the +41-kb Irf8 enhancer in CDPs, potentially by E-proteins, induced Irf8 expression and subsequent cDC1 fate specification. Similarly, other transiently acting networks may induce factors such as PU.1 or GATA1 in progenitors of other lineages. These networks may not be apparent in mature progeny, but might be revealed by the analysis of chromatin states of progenitors during development.
The present study also highlights how different enhancers of the same gene can be required at different stages of development of a single lineage. The development of cDC1s requires both the +41-kb and the +32-kb Irf8 enhancers, but the requirements are manifested at different developmental stages. The +41-kb Irf8 enhancer is required for the specification of pre-cDC1s from CDPs, but its activity is subsequently extinguished and is not apparent in the fully developed cDC1. On the other hand, the +32-kb Irf8 enhancer is active only after cDC1 specification and remains active in the fully developed cDC1. The switch between these two enhancers reveals that different transcriptional networks are responsible for Irf8 expression during distinct periods of cDC1 development. Such switches in enhancer activity could occur throughout hematopoiesis and their analysis could help elucidate the mechanisms controlling other fate divergences that are still not fully understood.
Finally, the finding of the present study that E-proteins were potentially responsible for cDC1 specification was wholly unexpected. However, as pDC development also relies on E-proteins, it is unclear how cDC1 and pDC fates are separately specified. Other factors important in cDC1 development, such as Id2, could act to exclude pDC potential by blocking E-protein activity, but why this would not also block cDC1 specification is unclear. Future work will need to determine the precise sequence of transcriptional events that governs cDC1 development, including the newfound role for E-proteins.
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Methods

Mice. Batf3 -/-
,
Irf8
-/-and Zbtb46 GFP/+ mice have been described previously 14, 21 .
-/-and Irf8 +41 -/-mice were newly generated as described below. The following mice were purchased from Jackson Laboratories: R26 
/J). Tcf3
-/-mice were a gift from B. Kee. All mice were on the C57BL6/J background except for Tcf3 -/-mice, which were on the FVB/NJ background. All mice were generated, bred and maintained at the Washington University in St Louis School of Medicine's specific pathogen-free animal facility. Animals were housed in individually ventilated cages covered with autoclaved bedding and provided with nesting material for environmental enrichment. Up to five mice were housed per cage. Cages were changed once a week and irradiated food and water in autoclaved bottles were provided freely. Animal manipulation was performed using standard protective procedures, including filtered air exchange systems, chlorine-based disinfection and personnel protective equipment, including gloves, gowns, shoe covers, facemasks and head caps. All animal studies followed institutional guidelines with protocols approved by the Animal Studies Committee at Washington University in St Louis.
Unless otherwise specified, experiments were performed with mice aged between 6 and 10 weeks. No differences were observed between male and female mice in any assays performed, so mice of both sexes were used interchangeably throughout the present study. Within individual experiments, mice used were age and sex matched whenever possible. When mice were tracked for tumor growth or survival after Salmonella enterica serovar typhimurium infection, the monitoring scientist was blinded as to the genotypes of the mice in the experiment.
Generation of Irf8 enhancer deletion mice. The sgRNAs that flanked the enhancers of interest were identified using GT-Scan (https://gt-scan.csiro. au/). For deletion of the Irf8 +32-kb enhancer, the following sgRNA sequences were used: Irf8 +32 5′: gttgtgatctttgaggtaga, Irf8 +32 mid: gtctccttctgaaatttcagtt and Irf8 +32 3′: gaactggcctggggcaggtc. For the Irf8 −50-kb enhancer the following sgRNA sequences were used: Irf8 −50 5′: ggtgacatctgtctacggag and Irf8 −50 3′: atgcacccaaggcctggctc. For the Irf8 +41-kb enhancer the following sgRNA sequences were used: Irf8 +41 5′: ggcccttgtagtttagctta and Irf8 +41 3′: aaagaagatctggggtatgt. Oligonucleotides that included these desired sgRNA sequences, preceded by a T7 polymerase initiation site (ttaatacgactcactataggg) and followed by a portion of the tracrRNA sequence that annealed to the pX330 vector (gttttagagctagaaatagcaag), were then purchased (Sigma-Aldrich). For example, the full Irf8 +32 5′-oligonucleotide purchased w as T TAATACGACTC ACTATAGGGgttgtgatctttgaggtagaGTTTTAGAGCTAGAAATAGCAAG. Each oligonucleotide was used in a PCR reaction with the PX330 Common Reverse Primer, aaaagcaccgactcggtgcc, and with the PX330 vector as a template to generate a complete DNA product containing the T7 polymerase initiation site, the sgRNA sequence and the full trans-activating CRISP (cr)RNA (tracrRNA) sequence in order. RNA was then synthesized from these products using the MEGAscript T7 Transcription Kit (Thermo Fisher Scientific). RNA was purified using the MEGAclear Transcription Clean-Up Kit (Thermo Fisher Scientific) and eluted into nuclease-free injection buffer. RNA was diluted and stored at −80 °C until it was used for microinjection. Purified Cas9 mRNA was a gift from W. Yokoyama.
Day 0.5 single-cell embryos from C57Bl/6 mice were isolated and underwent pronuclear microinjection at the Department of Pathology Micro-Injection Core. Each embryo was injected with 50 ng of each sgRNA and 100 ng of Cas9 mRNA. Injected embryos were then transferred into the oviducts of pseudopregnant recipient mice.
The resulting pups were screened by PCR to identify those that had successful deletion of the enhancers of interest. Mice with the desired deletion were then outcrossed to WT C57Bl/6 mice and the resulting heterozygous mice were intercrossed to generate homozygous enhancer deletion mice. DC preparation. Lymphoid and non-lymphoid organ DCs were harvested and prepared as described previously 49 . Briefly, spleens and inguinal skin-draining LNs were minced and digested in 5 ml of Iscove's modified Dulbecco's media (IMDM) +10% FCS (cIMDM) with 250 µg m -1 of collagenase B (Roche) and 30 U ml -1 of DNaseI (Sigma-Aldrich) for 45 min at 37 °C with stirring. Lungs were minced and digested in 5 ml of cIMDM with 4 mg ml -1 of collagenase D (Roche) and 30 U ml -1 of DNaseI (Sigma-Aldrich) for 1.5 h at 37 °C with stirring. After digestion was complete, single-cell suspensions from all organs were passed through 70-µm strainers and red blood cells were lysed with ammonium chloride-potassium bicarbonate (ACK) lysis buffer. Cells were subsequently counted with a Vi-CELL analyzer (Beckman Coulter) and 3-5 × 10 6 cells were used per antibody staining reaction.
For peritoneal cell analysis, 5 ml of MACS buffer (Dulbecco's phosphatebuffered saline + 0.5% BSA +2 mM ethylenediaminetetraacetic acid (EDTA)) was injected into the peritoneum of mice using a 27-g needle. After injection the mice were shaken gently to dislodge peritoneal cells. A 25-g needle was then used to collect the peritoneal fluid. Cells were lysed with ACK buffer and counted as described above. For intracellular IRF8/IRF4 staining, cells were stained for surface markers and then fixed/permeabilized with the intracellular fixation and permeabilization buffer kit (eBioscience) for 1 h overnight at 4 °C. Cells were then stained for 1 h at room temperature with intracellular antibodies. The cells were then washed and analyzed by flow cytometry. BM isolation. BM was harvested from the femur, tibia and pelvis of mice. Bones were collected and fragmented by mortar and pestle in MACS buffer, and debris was removed by passing cells through a 70-µm strainer. Red blood cells were lysed with ACK lysis buffer and cells were subsequently counted on a Vi-CELL analyzer (Beckman Coulter), with 3-5 × 10 6 being used per antibody staining reaction. For BM culture experiments, bulk BM cells were cultured at 37 °C in 4 ml total volume of cIMDM supplemented with 100 ng ml -1 of Flt3L (Peprotech) for 9 d before further analysis.
Progenitor sorting and culture. For sorting experiments, BM was isolated as described above and depleted of CD3-, CD19-, CD105-, Ter119-and Ly6G-expressing cells by staining with the corresponding biotinylated antibodies followed by depletion with MagniSort Streptavidin Negative Selection Beads (Thermo Fisher). All remaining BM cells were then stained with fluorescent antibodies before sorting. Gates used to define MDPs, CDPs and pre-cDC1s were a combination of previously established markers 21 
CD117
hi BM cells were sorted as described above and transduced with viral supernatants by 'spin infection' at 1,800g for 1 h in the presence of 2 µg ml -1 of polybrene. Infected cells were then cultured in Flt3L for 8 d before DCs were analyzed by flow cytometry. For in vitro CRISPR/ Cas9 deletion, Lin -CD117 hi BM cells from R26 Cas9/+ mice were sorted and the same transduction protocol was used.
The retroviral reporter vector (Thy1.1 pA GFP CMVp_min PmeI MCS RV) was generated by replacing the XhoI-EcoRI fragment containing the IRES-GFP from the MSCV-IRES-GFP vector 50 with a XhoI-EcoRI fragment containing IRES Thy1.1 from the MSCV-IRES-Thy1.1 vector 51 to produce the Thy1.1-only RV. The SalI-BamHI fragment from hCD4 pA GFP RV 52 containing GFP-K b pA was then blunted using Pfu polymerase and inserted into the blunted EcoRI site of Thy1.1-only RV to produce a Thy1.1 pA GFP RV vector. Annealed oligos containing PmeI sites and NcoI and HindIII overhangs (CATGGTGGCATCCACTAGTTCTAGGATCCGTTTAAACA and AGCTTGTTTAAACGGATCCTAGAACTAGTGGATGCCAC) were then ligated into the NcoI-HindIII-digested Thy1.1 pA GFP RV vector to produce the Thy1.1 pA GFP PmeI-MCS RV vector. A PCR product containing the minimal cytomegalovirus promoter (CMVp_min) and BamHI/BglII sites was then amplified from the green fluorescent protein (GFP) CMVp_min vector 43 and ligated into the BamHI site of the Thy1.1 pA GFP PmeI-MCS RV vector to produce the final Thy1.1 pA GFP CMVp_min PmeI-MCS RV vector. Enhancer regions were cloned into this vector using HindIII and BamHI digests.
. Briefly, in vitro LPSstimulated B cells were subjected to crosslinking at room temperature for either 10 min with 1% formaldehyde (single crosslinking) or for 45 min with 2 mM disuccinimidyl glutarate (Sigma-Aldrich), followed by 10 min with 1% formaldehyde (double crosslinking). The chromatin was prepared as previously described 54 . The pelleted genomic DNA, crosslinked with proteins, was sheared with a Bioruptor sonicator (Diagenode), followed by immunoprecipitation using an anti-E2A antibody. The precipitated DNA (1-2 ng) was used for library preparation and sequencing.
ATAC-seq. ATAC-seq of DC progenitors was performed using the Omni-ATAC protocol as previously described with minor modifications 34 . MDPs, CDPs and pre-cDC1s (total 10,000) were sorted from BM as described above and lysed in ice-cold ATAC-RSB buffer containing 0.1% NP40, 0.1% Tween-20 and 0.01% digitonin. Cells were incubated at 4 °C for 3 min, then washed with ATAC-RSB buffer containing only 0.1% Tween-20. Nuclei were spun down by centrifugation and then incubated in 50 µl of transposition buffer (25 µl of 2× TD buffer, 22.5 µl of distilled H 2 O, 2.5 µl of Tn5 transposase (Nextera DNA Library Prep Kit, Illumina)) and incubated at 37 °C for 30 min. If 10,000 cells could not be obtained for a certain population, then the quantity of Tn5 transposase was titrated down proportionately to the number of cells obtained, but cells were still incubated in 50 µl total. Transposed DNA was purified with a DNA Clean & Concentrator kit (Zymo Research), eluted in 21 µl of elution buffer and stored at −20 °C until amplification. Three biological replicates for each cell population were obtained and sequenced. ATAC-seq libraries were prepared as previously described, barcoded and sequenced on an Illumina Nextseq 500.
ATAC-seq of cDC1s, pDCs, monocytes, peritoneal macrophages, neutrophils and follicular B cells was obtained from the Immunological Genome Project Open Chromatin Regions 48 . ATAC-seq of LPS-activated B cells has been described previously 42 .
Computational analysis. For computational analysis of ATAC-seq of DC progenitors, adapter sequences were trimmed using SeqPurge and aligned to mm10 genome using bowtie2. These reads were then filtered for mitochondrial reads, low mapping quality (samtools flag '-F 1804 -f 2 -q 20') and PCR duplicates using Picard tools MarkDuplicates. The bam was then converted to a bed and the Tn5 corrected insertion sites were obtained ('+' stranded +4 bp, '−' stranded -5 bp) 33 . To identify peaks, peaks for each sample were named, using MACS2, '--shift -75 --extsize 150 --nomodel --call-summits --nolambda --keep-dup all -q 0.01' using the insertion beds. To get a union peak set, the peak summits were then extended by 250 bp on either side to a final width of 501 bp, filtered by the ENCODE mm10 blacklist (https://www.encodeproject.org/annotations/ ENCSR636HFF/) and filtered to remove peaks that extend beyond the ends of chromosomes. Overlapping peaks were handled using an iterative removal procedure as previously described 55 . First, the most significant peak (defined by MACS2 score) is kept and any peak that directly overlaps with that significant peak is removed. Then, this process repeats to the next most significant peak and so on until all peaks have either been kept or removed due to direct overlap with a more significant peak. This resulted in a union peak set of 188,509 equalwidth peaks. These peaks were then annotated using ChIPseeker, computing the occurrence of a TF motif using motifmatchr in R with chromVARMotifs mouse_pwms_v1 set 56 . All insertions that fell within each peak were then counted using 'countOverlaps' in R to get a counts matrix (peak × samples). To determine differential peaks, the raw counts matrix was used as input into DESeq2 using the modelMatrixType = 'expanded' and were tested for whether or not a peak was greater than a log 2 (fold change) of 0.5 (lfcThreshold = 0.5, altHypothesis = 'greaterAbs') 57 . A cutoff of a false discovery rate (FDR) <0.1 was used to denote a differential peak. For clustering analyses, the counts matrix was then normalized by using edgeR's 'cpm(matrix, log = TRUE, prior.count = 5)' , followed by a quantile normalization using preprocess Core's 'normalize.quantiles' in R. TF motif enrichment was calculated using a hypergeometric test in R, testing the representation of a motif (from motifmatchr above) in a subset of peaks versus all peaks. To compute TF motif deviations, chromVAR was used in R with raw counts in distal peaks (defined as >1 kb from a TSS in TxDb.Mmusculus.UCSC. mm10.knownGene) and then the top 100 variable TF motifs were determined using variability scores 56 . To create sequencing tracks, the Tn5-corrected insertion sites were read into R and a coverage pileup was created, which was binned every 100 bp using rtracklayer and normalized by reads in peak such that they were all scaled to 30 M total reads in peaks (from counts matrix).
Data availability.
The sequencing and microarray data generated during the course of this study have been deposited and are available on the Gene Expression Omnibus database. The ChIP-seq data of DC progenitors used in Fig. 3 can be accessed with the following accession number: GSE132239. The ATAC-seq data of DC progenitors used in Figs. 5 and 6 can be accessed with the following accession number: GSE132240.
The microarrays utilized in Supplementary Fig. 4 can be accessed with the following accession numbers: GSE123747, GSE132767 and GSE132768. All other primary data and materials that support the findings of this study are available from the corresponding author upon request.
